Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Self-amplifying mRNA influenza virus vaccine A(H1N1) - Seqirus

Drug Profile

Self-amplifying mRNA influenza virus vaccine A(H1N1) - Seqirus

Alternative Names: A(H1N1) - Seqirus

Latest Information Update: 19 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seqirus
  • Class Influenza A virus H1N1 vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype

Most Recent Events

  • 05 Oct 2023 Phase-I clinical trials in Influenza A virus H1N1 subtype (Prevention) in Australia (unspecified route) (NCT06028347)
  • 11 Sep 2023 Seqirus plans a phase I trial in Influenza virus infections (Prevention) in September 2023 (NCT06028347)
  • 01 Nov 2022 Arcturus enters into a collaboration with Seqirus to develop and commercialize self-amplifying mRNA vaccines
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top